MET and non-small cell lung carcinoma: Relevant data are provided by the phase II VISION trial of tepotinib, a highly selective, oral, once-daily MET tyrosine kinase inhibitor, in patients with advanced NSCLC with MET exon 14 (METex14) skipping (9–11), which is a predictive marker for MET inhibitors (12).